Type 1 diabetes and engineering enhanced islet transplantation

Jeyagaran, Abiramy; Lu, Chuan-En; Zbinden, Aline; Birkenfeld, Andreas L.; Brucker, Sara; Layland, Shannon L.

doi:10.1016/j.addr.2022.114481

Cited by 27 publications

(15 citation statements)

References 474 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, this strategy holds great significance in exploring new extrahepatic transplantation sites and stem cell-derived islet cells. 2…”

Section: Reviewmentioning

confidence: 99%

“…1 The current primary treatment for T1D requires daily insulin injections, which result in long-term financial burdens, adverse reactions, and complications. 2 Islet transplantation offers a promising alternative that is expected to achieve stable long-term metabolic control while circumventing the complexities and associated complications of conventional treatment. 3 The Edmonton protocol, the first systematic clinical protocol for islet transplantation, was introduced in 2000 and is regarded as the most significant milestone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

Qi,

Ding,

Zhang

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…Consequently, this strategy holds great significance in exploring new extrahepatic transplantation sites and stem cell-derived islet cells. 2…”

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

Qi,

Ding,

Zhang

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…Diabetes is a chronic metabolic disease that lasts a lifetime, especially type I diabetes, which requires frequent subcutaneous injections of insulin (INS) to maintain blood glucose balance [ 1 , 2 ]. However, such a pathway may lead to poor patient compliance and hypoglycemia.…”

Section: Introductionmentioning

confidence: 99%

pH-Responsive and Mucoadhesive Nanoparticles for Enhanced Oral Insulin Delivery: The Effect of Hyaluronic Acid with Different Molecular Weights

et al. 2023

View full text Add to dashboard Cite

Drug degradation at low pH and rapid clearance from intestinal absorption sites are the main factors limiting the development of oral macromolecular delivery systems. Based on the pH responsiveness and mucosal adhesion of hyaluronic acid (HA) and poly[2-(dimethylamino)ethyl methacrylate] (PDM), we prepared three HA–PDM nano-delivery systems loaded with insulin (INS) using three different molecular weights (MW) of HA (L, M, H), respectively. The three types of nanoparticles (L/H/M-HA–PDM–INS) had uniform particle sizes and negatively charged surfaces. The optimal drug loadings of the L-HA–PDM–INS, M-HA–PDM–INS, H-HA–PDM–INS were 8.69 ± 0.94%, 9.11 ± 1.03%, and 10.61 ± 1.16% (w/w), respectively. The structural characteristics of HA–PDM–INS were determined using FT-IR, and the effect of the MW of HA on the properties of HA–PDM–INS was investigated. The release of INS from H-HA–PDM–INS was 22.01 ± 3.84% at pH 1.2 and 63.23 ± 4.10% at pH 7.4. The protective ability of HA–PDM–INS with different MW against INS was verified by circular dichroism spectroscopy and protease resistance experiments. H-HA–PDM–INS retained 45.67 ± 5.03% INS at pH 1.2 at 2 h. The biocompatibility of HA–PDM–INS, regardless of the MW of HA, was demonstrated using CCK-8 and live–dead cell staining. Compared with the INS solution, the transport efficiencies of L-HA–PDM–INS, M-HA–PDM–INS, and H-HA–PDM–INS increased 4.16, 3.81, and 3.10 times, respectively. In vivo pharmacodynamic and pharmacokinetic studies were performed in diabetic rats following oral administration. H-HA–PDM–INS exhibited an effective hypoglycemic effect over a long period, with relative bioavailability of 14.62%. In conclusion, these simple, environmentally friendly, pH-responsive, and mucoadhesive nanoparticles have the potential for industrial development. This study provides preliminary data support for oral INS delivery.

show abstract

“…Accompanied by population aging and dietary change, the global prevalence of DM rises steadily [ 2 ]. Type 1 DM usually occurs in adolescents and is featured by the absolute deficiency of insulin secretion due to pancreatic islet β-cells reduction [ 3 ]. Type 2 DM is common in elder and obese patients because of the decreased insulin sensitivity of peripheral tissues and reduced insulin secretion of pancreatic islet β-cells [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapy for Diabetes Mellitus and Diabetic Complications

Sun

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

As a novel cell-free strategy, mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) inherit the therapeutic potential of donor cells, and are widely used for the treatment of many diseases. Increasing studies have shown that MSC-EVs transfer various bioactive molecules to create a beneficial microenvironment, thus exerting protective roles in diabetic mellitus (DM) and diabetic complications. To overcome the limitations of natural MSC-EVs such as heterogeneity and insufficient function, several modification methods have been established for constructing engineered MSC-EVs with elevated repairing efficiency. In this review, the PubMed library was searched from inception to August 2022, using a combination of Medical Subject Headings (MeSH) and keywords related to MSC-EVs, DM, and diabetic complications. We provide an overview of the major characteristics of MSC-EVs and summarize the recent advances of MSC-EV-based therapy for hyperglycemia-induced tissue damage with an emphasis on MSC-EV-mediated delivery of functional components. Moreover, the potential applications of engineered MSC-EVs in DM-related diseases therapy are discussed by presenting examples, and the opportunities and challenges for the clinical translation of MSC-EVs, especially engineered MSC-EVs, are evaluated.

show abstract

Type 1 diabetes and engineering enhanced islet transplantation

Cited by 27 publications

References 474 publications

Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

pH-Responsive and Mucoadhesive Nanoparticles for Enhanced Oral Insulin Delivery: The Effect of Hyaluronic Acid with Different Molecular Weights

Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapy for Diabetes Mellitus and Diabetic Complications

Contact Info

Product

Resources

About